On April 1, 2018, a discussion meeting on the protocol of a single-arm, open-label, multi-center Phase Ib/IIa clinical study of CHA for injection in the treatment of advanced lung cancer was held at Guangxi Building in Beijing.

All the subjects participating in the Phase I clinical trial of CHA for injection were patients with high - grade malignant gliomas who had failed international standard treatments such as surgery, radiotherapy and chemotherapy. The results of the Phase I clinical trial prove that CHA injection is safe with extremely low toxic and side effects. Its pharmacokinetic pathway is clear and there is no cumulative toxicity. The treatment effect exceeds the researchers' expectations. For recurrent patients who have failed the classic treatment methods, after using CHA for injection, their median overall survival time is at least 2 to 5 times longer than the globally recognized one.

The "2nd China Pharmaceutical Innovation and Investment Conference" was held at the Suzhou Jinji Lake International Convention Center on October 29, 2017. Jiuzhang Biotech released the Phase I clinical trial data on the safety, tolerability and pharmacokinetics of CHA for injection in the treatment of advanced malignant gliomas.

Sichuan Jiuzhang Biotechnology Co., Ltd. has established a strategic technical research and development cooperation relationship with the Institute of Materia Medica of the Chinese Academy of Medical Sciences (affiliated to the Chinese Academy of Medical Sciences; its academic and professional title system falls under Peking Union Medical College, and it is a national key drug research institution). The two parties jointly established the "Chlorogenic Acid Cooperative Development Project Committee" to jointly conduct research on the pharmacological mechanism of chlorogenic acid and promote the transformation of basic research achievements into clinical applications.

In November 2016, the inventor Zhang Jie, Professor Chen Xiaoguang, the researcher of the anti-tumor mechanism of CHA, and Professor Li Wenbin, the main researcher of the glioma clinical research (PI), received an exclusive interview from the reporter of Nature magazine. The interview content was published in Nature on December 22, 2016.

hang Jie, the inventor (from Jiuzhang Biotech), released the clinical data of CHA for injection at the conference. The "China Pharmaceutical Innovation and Investment Conference" was held at the Suzhou Jinji Lake International Convention Center on November 14, 2016. Jiuzhang Biotech released the phased clinical research data of the CHA for injection preparation.